Trial · NCT02109445
Adverse events26
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 26
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Ascites | Gastrointestinal disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Nausea | Gastrointestinal disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 2 | 3 | |
| other | Vomiting | Gastrointestinal disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 2 | 3 | |
| other | Chills | General disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Fatigue | General disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 3 | 3 | |
| other | Mucosal inflammation | General disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Candida infection | Infections and infestations | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Fall | Injury, poisoning and procedural complications | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Alanine aminotransferase increased | Investigations | PF-03084014+Nab-Paclitaxel+Gemcitabine | 2 | 3 | |
| other | Aspartate aminotransferase increased | Investigations | PF-03084014+Nab-Paclitaxel+Gemcitabine | 2 | 3 | |
| other | Blood bilirubin increased | Investigations | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Decreased appetite | Metabolism and nutrition disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Failure to thrive | Metabolism and nutrition disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Hypokalaemia | Metabolism and nutrition disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Hypophosphataemia | Metabolism and nutrition disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Dizziness | Nervous system disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Anxiety | Psychiatric disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Depression | Psychiatric disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Hallucination | Psychiatric disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | PF-03084014+Nab-Paclitaxel+Gemcitabine | 1 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02109445/events